SARAH KENT: Open Payments
NPI 1093011231 · VALHALLA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,920 in 84 payments from 11 companies in 2025. Trend: 2023 $3,893 · 2024 $3,728 · 2025 $2,920
Food & beverage: $2,915Education: $6
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $857 |
| Janssen Pharmaceuticals, Inc | 4 | $535 |
| Alkermes, Inc. | 10 | $383 |
| Otsuka America Pharmaceutical, Inc. | 18 | $278 |
| Neurocrine BioSciences, Inc. | 4 | $196 |
| Teva Pharmaceuticals USA, Inc. | 3 | $147 |
| Axsome Therapeutics, Inc. | 2 | $140 |
| Lilly USA, LLC | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 6 | $107 |
| Almatica Pharma LLC | 3 | $81 |
Products named: CAPLYTA, INVEGA SUSTENNA, LYBALVI, REXULTI, INGREZZA, Auvelity, KISUNLA, COBENFY.
Industry payments across NY — which companies pay providers there.
